Hartmann, Pia and Lammertink, J. and Mansmann, G. and Hubel, K. and Salzberger, Bernd and Stuetzer, H. and Engert, A. and Faetkenheuer, G. (2005) A randomized, placebo-controlled study of the use of filgrastim in non neutropenic patients with nosocomial pneumonia. EUROPEAN JOURNAL OF MEDICAL RESEARCH, 10 (1). pp. 29-35. ISSN 0949-2321,
Full text not available from this repository. (Request a copy)Abstract
Pneumonia remains the number one cause of death from infectious diseases in Western Europe and the United States despite the introduction of potent broad-spectrum antibiotics. Granulocyte colony-stimulating factor is considered to improve host defense during infection and may be an effective adjunctive in the treatment of severe infections. We examined the efficacy of granulocyte colony-stimulating factor (r-metHUG-CSF, filgrastim) with regard to clinical response in non-neutropenic ICU patients with nosocomial pneumonia in a prospective, randomized, placebo-controlled trial. 28 patients with newly diagnosed nosocomial pneumonia were randomly assigned to receive 300-480 mug filgrastim or placebo subcutaneously for up to seven days. Study endpoints were death within 15 days, duration of antibiotic therapy and occurrence of serious adverse events (SAE). No significant differences were observed in respect of 15-day (filgrastim 1/12 vs. placebo 2/16) or 30-daNT P mortality (1/12 vs. 4/16, p = 0.355), and length of antibiotic treatment (13.5 vs. 11.5 days, p = 0.985). Sepsis developed in 1/12 patients in the filgrastim and 6/16 patients in the placebo group (p = 0.184). None of the patients developed ARDS or any other SAE related to the stud T medication. Filgrastim is safe in non-neutropenic ICU patients with nosocomial pneumonia. A benefit of filgrastim with regard to clinical endpoints could not be observed, while there was a trend toward reduced sepsis rate.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | COLONY-STIMULATING FACTOR; BLOOD CYTOKINE CONCENTRATIONS; COMMUNITY-ACQUIRED PNEUMONIA; INTENSIVE-CARE PATIENTS; RHG-CSF; ATTRIBUTABLE MORTALITY; INFLAMMATORY RESPONSE; GRANULOCYTE FUNCTION; INFECTIOUS-DISEASES; VENTILATED PATIENTS; granulocyte-colony stimulating factor; nosocomial pneumonia; intensive care; sepsis |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin I |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 31 May 2021 08:05 |
| Last Modified: | 31 May 2021 08:05 |
| URI: | https://pred.uni-regensburg.de/id/eprint/36577 |
Actions (login required)
 |
View Item |
